iSAP-0913 / ISAP Biotech - LARVOL DELTA

A novel in vivo self-assembled peptide-drug conjugate targeting HER2 with potent anti-tumor efficacy overcoming resistance of HER2 ADCs (AACR 2025) - "The in vivo anti-tumor efficacy was assessed in a DS8201-induced NCI-N87 resistance model. Comprehensive preclinical data have supported iSAP-0913 as a promising PDC candidate for HER2-low expression and/or patients insensitive to other HER2-targeting ADCs, particularly as a sequential treatment following resistance to HER2 ADCs. iSAP-0913 is now undergoing preclinical development."

Preclinical • Oncology • HER-2